Browsing Tag
Bayer
27 posts
Microsoft (MSFT) trades near $424 after Q3 beat as OpenAI revenue share is eliminated
Microsoft beat Q3 expectations across the board. Then it guided $190 billion of 2026 capex and Q4 revenue below consensus. Read more.
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
EYLEA HD and DUPIXENT anchor Regeneron’s 2026 growth plan amid clinical pipeline acceleration
Find out how Regeneron’s 18 new Phase III trials and four FDA approval targets in 2026 aim to reshape growth beyond DUPIXENT and EYLEA. Read the full story.
Organon (NYSE: OGN) secures FDA approval for five-year use of NEXPLANON contraceptive implant, adding new REMS training requirement
Find out how Organon’s NEXPLANON just got FDA approval for five-year use—and what the new REMS program means for doctors and competitors.
Is Bayer’s Roundup litigation strategy finally gaining legal traction with U.S. Supreme Court review?
Bayer's Roundup strategy just got a Supreme Court boost. Find out what the Durnell review could mean for tort law, federal preemption, and investor sentiment.
Biocon Biologics (NSE: BIOCON) clears global aflibercept deal with Regeneron, Bayer for Yesafili rollout
Biocon Biologics secures global aflibercept launch rights for Yesafili after Regeneron–Bayer settlement. Find out what this means for biosimilar strategy.
Hyrnuo secures FDA approval as Bayer expands precision oncology in HER2-driven lung cancer
FDA approval of Bayer’s Hyrnuo opens a new targeted option for HER2-mutated lung cancer patients—find out how this therapy is reshaping precision oncology today.
Bayer’s FDA review extension for elinzanetant signals global push for hormone-free menopause therapies
Bayer receives FDA review extension for elinzanetant menopause drug; U.S. approval still likely, with global rollout underway and analysts optimistic.
Gadoquatrane heads to FDA: Can Bayer lead the next generation of low-dose MRI contrast agents?
Bayer targets FDA nod for gadoquatrane, the lowest‑dose macrocyclic MRI contrast agent, potentially reshaping radiology practices globally.
Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for…